C

Cyclopharm Ltd
ASX:CYC

Watchlist Manager
Cyclopharm Ltd
ASX:CYC
Watchlist
Price: 1.51 AUD Market Closed
Market Cap: 167.8m AUD
Have any thoughts about
Cyclopharm Ltd?
Write Note
CYC
/
Balance Sheet
/
Short-Term Debt

Cyclopharm Ltd
Short-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Cyclopharm Ltd
Short-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
C
Cyclopharm Ltd
ASX:CYC
Short-Term Debt
AU$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
R
Respiri Ltd
ASX:RSH
Short-Term Debt
AU$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ImpediMed Ltd
ASX:IPD
Short-Term Debt
AU$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cochlear Ltd
ASX:COH
Short-Term Debt
AU$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Optiscan Imaging Ltd
ASX:OIL
Short-Term Debt
AU$40.3k
CAGR 3-Years
N/A
CAGR 5-Years
-27%
CAGR 10-Years
-11%
EMvision Medical Devices Ltd
ASX:EMV
Short-Term Debt
AU$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Cyclopharm Ltd
Glance View

Market Cap
167.8m AUD
Industry
Health Care

Cyclopharm Ltd. is a radiopharmaceutical company, which engages in the diagnostic imaging in lung health. The company provides diagnostic imaging services specializing in lung health. The firm through its medical device and pharmaceutical products under the name of Technegas, which has become the industry in diagnostic functional lung imaging technology. The company distributes its products in approximately 60 countries throughout the world with over 1500 nuclear medicine departments utilizing Technegas. The firm formed a joint venture with Alfred Health Solutions and Macquarie University Hospital to provide various imaging services on-site at the hospital. The Macquarie Medical Imaging (MMI) offers a range of diagnostic radiology, interventional radiology, nuclear medicine and molecular imaging services for inpatient and outpatients. Its Ultralute is a device that extends the useful life of Molybdenum-99 (Mo-99) generators.

CYC Intrinsic Value
2.04 AUD
Undervaluation 26%
Intrinsic Value
Price
C
What is Intrinsic Value?

See Also

What is Cyclopharm Ltd's Short-Term Debt?
Short-Term Debt
0 AUD

Based on the financial report for Jun 30, 2024, Cyclopharm Ltd's Short-Term Debt amounts to 0 AUD.

Back to Top
ALPHA SPREAD
Follow us
Join more than 211,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.